Pephexia is happy to announce that a clinical candidate has been nominated from Pephexia’s lead program in cancer cachexia. As a next step the drug candidate, a metabolic peptide, will be progressed towards clinical development through regulatory and CTA-enabling non-clinical studies.

Reflecting this significant progress Pephexia is delighted to welcome two excellent new clinical advisors – Dr. Jonas Sørensen and Prof. Lars J. Pedersen – who with their elaborate clinical experience within cancer and cachexia fields will support the further development of our clinical candidate.

Finally, Pephexia is very pleased to receive a second industrial Postdoc grant from the Innovation Fond Denmark for Camilla Lund, PhD. Camilla comes with a strong background in metabolic research and will in collaboration with Associate Professor Lykke Sylow strengthen the understanding of the mode-of-actions of metabolic peptides in cancer cachexia.

We are pleased to announce that Pephexia Therapeutics ApS has entered a Research Collaboration with Assistant Professor Marc Schneeberger Pané at Yale University. With state-of-the-art imaging technologies Dr. Schneeberger Pane laboratory is investigating how neuronal, immune, and vascular networks coordinately control energy homeostasis. The collaboration aims at investigating the mode-of-action (MoA) of novel peptide drug candidate developed by Pephexia Therapeutics and will strengthen Pephexia’s ambition to bring novel innovative cancer cachexia therapeutics to the market.

We are very happy to announce that Pephexia Therapeutics ApS has entered a research collaboration with Wouter van de Worp at Maastricht University. Dr. Van de Worp, in the group of Dr. Ramon Langen, has developed orthotopic mouse models of cancer cachexia with improved translatability to the human situation. The collaboration aims at characterizing novel peptide therapeutics developed by Pephexia Therapeutics and highlights Pephexia’s ambition to bring novel innovative cancer cachexia therapeutics to the market.

Pephexia has again strengthened the team and added 2 experienced bio-tech profiles and it’s a pleasure to announce that Charlotte Videbæk joins as Medical Advisor and Jan K. Villadsen as Financial Advisor. 

Pephexia Therapeutics ApS have received a Grant of 4.7M DKK from the Danish Innovation Fund. This is the second grant following the successful execution of the first minor Innobooster project. Now in the second major Innobooster project it is the intention to mature Pephexia lead project for Cancer Cachexia towards Lead selection and characterization.

Pephexia has received a financing of 3M DKK/400.000 Euro from Vækstfonden (Danish Growth Fund). This funding enable advancement of our innovative peptide projects for the treatment of cachexia at full speed towards lead selection and characterization.

MEDWATCH.DK

Kamilla Rolsted joins a newly created position as Chief Business Officer (CBO) in Pephexia Therapeutics. Kamilla brings solid experience from positions in companies such as Zealand Pharma, Bionor Pharma, and Akari Therapeutics.

MEDWATCH.DK

Entering the Creation House program at BII is a major milestone in Pephexia’s efforts towards the development of effective and convenient treatments of cachexia and related diseases.

BII.DK

Pephexia Therapeutics ApS have received a Grant of 4.7M DKK from the Danish Innovation Fund. This is the second grant following the successful execution of the first minor Innobooster project. Now in the second major Innobooster project it is the intention to mature Pephexia lead project for Cancer Cachexia towards Lead selection and characterization.

Pephexia strengthens its knowhow on peptide drug discovery by welcoming Søren Ljungberg Pedersen as new CTO & Head of Research and Professor Annette G. Beck-Sickinger as Scientific advisor.

Pephexia has received a financing of 3M DKK/400.000 Euro from Vækstfonden (Danish Growth Fund). This funding enable advancement of our innovative peptide projects for the treatment of cachexia at full speed towards lead selection and characterization.

MEDWATCH.DK

Kamilla Rolsted joins a newly created position as Chief Business Officer (CBO) in Pephexia Therapeutics. Kamilla brings solid experience from positions in companies such as Zealand Pharma, Bionor Pharma, and Akari Therapeutics.

MEDWATCH.DK

Entering the Creation House program at BII is a major milestone in Pephexia’s efforts towards the development of effective and convenient treatments of cachexia and related diseases.

BII.DK

From hundreds of high-quality applications the Nordic Selection Committee has chosen Pephexia Therapeutics as one of the Rising Stars to join Nordic Life Science Invest. Pephexia Therapeutics is pleased to be able to pitch before 120+ global investors joining the NLSInvest & Nordic Life Science Days.

NLSINVEST.COM

Pephexia strengthens its knowhow on peptide drug discovery by welcoming Søren Ljungberg Pedersen as new CTO & Head of Research and Professor Annette G. Beck-Sickinger as Scientific advisor.

A team of senior people in biotech join forces in a new biotech company set out to develop a novel medicine for unintended weight loss.

MEDWATCH.DK

Today Pephexia has received an Innobooster grant from Innovationsfonden, Denmark for funding of the lead peptide program for cachexia.

Pephexia has expanded the share capital by inclusion of active private investors for acceleration of the lead peptide program for cachexia.